MarketMoodz
FDA Panel to Review Moderna’s mRNA Flu Shot for Adults
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet June 18 to review Moderna’s mRNA-1010 (mFlusiva), a trivalent mRNA influenza vaccine, potentially clearing a path to full approval for adults 50–64 and accelerated approval for adults 65+. The panel will focus on comparator choice, efficacy against B/Victoria, use of immunogenicity as a surrogate endpoint, and whether single-season data are sufficient—questions that will influence labeling, postmarketing commitments and market access ahead of a PDUFA goal date of August 5, 2026.
Key Takeaways
- VRBPAC meets June 18 to review Moderna’s mRNA-1010 (mFlusiva) for adults 50–64 and 65+.
- FDA lists a PDUFA goal date of August 5, 2026 for the application.
- Key questions include whether the standard-dose comparator was appropriate, efficacy vs B/Victoria, single-season data sufficiency, and immunogenicity as a surrogate.
- Moderna’s planned pathway contemplates full approval for ages 50–64 and accelerated approval for 65+ with a postmarketing study for older adults.
- Analysts see upside to Moderna’s 2027 revenue if approved, though postmarketing commitments and labeling remain unclear.
People Involved
- Myles MinterAnalyst
Entities Involved
- Moderna, Inc. (MRNA)Developer of mRNA-1010 (mFlusiva) influenza vaccine
- FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC)Advisory panel reviewing Moderna's application
- William BlairInvestment bank/analyst firm commenting on revenue impact
- European regulatorsCited as broader context for mRNA vaccine momentum
MarketMoodz Analysis
For investors, the VRBPAC meeting is a binary near-term event with meaningful optionality. A favorable advisory vote and a clean FDA decision ahead of the August 5 PDUFA date would validate mRNA as a platform beyond COVID and could unlock pricing and payer negotiations ahead of the 2027 season—analysts at William Blair and others project potential revenue upside next year if Moderna secures favorable labeling. Conversely, a vote that questions the comparator or the reliance on immunogenicity as a surrogate, or that highlights limited single-season efficacy data, could postpone approval, impose restrictive labeling or demand substantial postmarketing commitments that push material revenue further out.
This review sits against a backdrop of regulatory rigor and competition. The company reportedly received a refusal-to-file in February (per earlier reports), underscoring FDA scrutiny around comparator selection and trial design; the current meeting will test whether Moderna addressed those concerns. Historically, influenza vaccine approvals hinge on appropriate comparators and demonstrated clinical effectiveness across seasons—immunobridging helps, but regulators expect robust justification. Watch the VRBPAC’s stance on the standard-dose comparator, the committee’s view of B/Victoria efficacy data, how comfortably it accepts immunogenicity as a surrogate, and the details of any post-approval study commitments; those signals will determine timing, label scope, and market uptake.
Source: Original Article